BioPharmSignal logoBioPharmSignal

Biotech News

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Roivant (ROIV)RoivantClinical readout

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials comprising the CLARITY program in NIU Median time to treatment failure for brepocitinib

Related news

ROIVRoivant2026-09-23 11:00 EST

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

ROIVRoivant2026-02-06 12:00 EST

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

View all latest news

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

ROIVRoivant2026-10-21 11:01 EST

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

ROIVRoivant2026-10-21 11:00 EST

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

ROIVRoivant2026-09-23 11:00 EST

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

ROIVRoivant2026-09-23 11:00 EST

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

ROIVRoivant2026-09-06 05:00 EST

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Stock data

Close
37.45 USD
Market cap
20.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States